Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia

Kikuya, Megumi; Furuichi, Kenta; Hirao, Takuya; Endo, Shunsuke; Toyooka, Naoki; Ito, Kousei; Aoki, Shigeki

doi:10.1016/j.jphs.2021.05.001

Cited by 3 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epalrestat has demonstrated significant anticancer effects in breast cancer[33], colorectal cancer[31], and liver cancer[34], both as a standalone treatment and in combination with cytotoxic chemotherapy and targeted therapeutics. Additionally, Kikuya et al [35] reported that epalrestat enhances the anticancer effects of tyrosine kinase inhibitors (imatinib, nilotinib, or bosutinib) in chronic myelogenous leukemia. This study provides a solid foundation for exploring the application of AKR1B1 inhibitors in combination with imatinib for the treatment of GISTs.…”

Section: Discussionmentioning

confidence: 99%

Multi-omics reveals AKR1B1-regulated galactose metabolic as a driver of gastrointestinal stromal tumor progression

Yin,

Yang,

Liu

et al. 2024

Preprint

View full text Add to dashboard Cite

The underlying mechanism of malignant progression in gastrointestinal stromal tumors (GISTs) is not fully understood. Despite recent advancements, a comprehensive profile of metabolome, transcriptome, and proteome of GISTs is lacking. This study conducted an integrated multi-omics analysis of GISTs across different risk classifications. By integrating metabolomics, transcriptomics, and proteomics, we identify distinct metabolic patterns and associated biological pathways implicated in the malignant progression of GISTs. Moreover, we identified galactose metabolism and the pivotal rate-limiting enzyme AKR1B1 is dysregulated in GISTs progression. AKR1B1 was upregulated and predicted poor prognosis in GISTs. In addition, AKR1B1 knockdown resulted in trehalose accumulation in GIST cells, thereby inhibiting cell proliferation and mitosis. These findings not only enhance our comprehension of the underlying mechanisms governing GIST progression from a metabolic reprogramming standpoint but also furnish prognostic biomarkers and potential therapeutic targets for GISTs.

show abstract

Section: Discussionmentioning

confidence: 99%